Transposable Elements Shape Stemness in Normal and Leukemic Hematopoiesis

Despite most acute myeloid leukemia (AML) patients achieving complete remission after induction chemotherapy, two thirds of patients will relapse with fatal disease within 5 years. AML is organized as a cellular hierarchy sustained by leukemia stem cells (LSC) at the apex, with LSC properties directly linked to tumor progression, therapy failure and disease relapse. Despite the central role of LSC in poor patient outcomes, little is known of the genetic determinants of their stemness properties. Although much AML research focuses on mutational processes and their impact on gene expression programs, the genetic determinants of cell state properties including stemness expand beyond mutations, relying on the genetic architecture captured in the chromatin of each cell. As LSCs share many functional and molecular properties with normal hematopoietic stem cells (HSC), we identified genetic determinants of primitive populations enriched for LSCs and HSCs in comparison with their downstream mature progeny by investigating their chromatin accessibility. Our work reveals how distinct transposable element families are used in primitive versus mature populations, functioning as docking sites for stem cell-associated regulators of genome topology or lineage-specific transcription factors in primitive and mature populations, respectively. We further show how transposable element families accessible in LSCs define docking sites for several oncogenic drivers in AML, including LYL1. Using chromatin accessibility profiles from a cohort of AML patients, we further show the clinical utility of our transposable element accessibility-based LSCTE121 scoring scheme to identify patients with high rates of relapse. Collectively, our work reveals how different accessible transposable element families serve as genetic determinants of stemness properties in normal and leukemic hematopoietic stem cells. Overall design: Assay for Transposase-Accessible Chromatin Sequencing (ATAC-Seq) performed on engrafting (LSC+) and non-egrafting (LSC-) leukemic cells and on bulk AML patients' peripheral blood samples *** Raw data for these needs controlled access hence are already submitted to EGA (EGAS00001004893, EGAS00001004896 and EGAS00001007191). *** Assay for Transposase-Accessible Chromatin Sequencing (ATAC-Seq) performed on OCI-AML22 CD34+/CD38- cells expressing CRISPR/dCas9 and scramble or LTR12C gRNA combos